AstraZeneca has received approval from the European Commission for the use of Dapagliflozin as an adjunct to insulin to treat type-1 diabetes. The indication covers adult patients with a BMI of 27 or more who often cannot achieve adequate glycaemic control with insulin alone, despite optimal therapy. Dapagliflozin is said to be the first AstraZeneca drug
Regulators in the EU and US are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to aid improvement of glycaemic control in adults with type II diabetes.
The European Commission has approved AstraZeneca’s Qtern, a two-drug therapy for type 2 diabetes that was turned down in the US last year. The diabetes therapy combines active ingredients in AZ’s DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), making it the second drug of its type on the market after Eli Lilly and
Boehringer Ingelheim and Eli Lilly Diabetes Alliance have announced that regulators for the National Health Service in England have deemed their drug, Jardiance (empagliflozin), as value for money. The drug has been recommended by the National Institute for Health and Care Excellence (NICE) for treating some patients with type II diabetes. The endorsement is a
Johnson & Johnson have announced that they have received regulatory approvals on both sides of the Atlantic for two of their key drugs, Olysio and Invokana. On Friday the US regulatory body, the Food and Drug Administration (FDA), approved Olysio (simeprevir) to treat chronic hepatitis C virus infection. The drug was co-developed by Johnson and
European regulators have approved Novo Nordisk’s Tresiba and Ryzodeg, which Novo hopes will challenge Sanofi’s Lantus, the largest selling insulin product globally. The European Commission have granted marketing authorisations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults.
Italy’s Dompe have confirmed that they have signed up their first patient onto a late-stage clinical trial evaluating reparixin as a possible treatment for type 1 diabetes. The compound, a selective chemokine interleukin-8 inhibitor, has been shown to increase the efficacy of transplantation of insulin-producing pancreatic islets, which the company commented is “the new frontier
Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor
Novo Nordisk has revealed plans to expand their treatment for diabetes in emerging markets by employing roughly 1,000 additional employees over the next two years. Some of the emerging markets that Novo Nordisk are planning to expand in include Egypt, Vietnam, Colombia, Malaysia, Ukraine and Indonesia. As the pharmaceutical market in Europe, for example, slows
Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is
